Free Trial
MarketBeat All Access — Now with A.I. InsightsStart My Trial

Allergy Therapeutics (LON:AGY) Share Price Crosses Above Fifty Day Moving Average - Here's What Happened

Written by MarketBeat
October 8, 2025
Allergy Therapeutics logo with Medical background

Key Points

  • Allergy Therapeutics shares have crossed above their 50-day moving average of GBX 8.29, reaching a recent high of GBX 8.45 during trading.
  • The company has a high debt-to-equity ratio of 835.48, a market capitalization of £381.32 million, and a negative PE ratio of -1,111.11.
  • Allergy Therapeutics specializes in the treatment and diagnosis of allergic disorders, selling proprietary and third party products across multiple European countries.
  • Five stocks to consider instead of Allergy Therapeutics.

Allergy Therapeutics plc (LON:AGY - Get Free Report) shares crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of GBX 8.29 ($0.11) and traded as high as GBX 8.45 ($0.11). Allergy Therapeutics shares last traded at GBX 8 ($0.11), with a volume of 665,596 shares.

Allergy Therapeutics Stock Performance

The company has a debt-to-equity ratio of 835.48, a current ratio of 1.63 and a quick ratio of 1.48. The firm has a market capitalization of £381.32 million, a PE ratio of -1,111.11, a price-to-earnings-growth ratio of -30.70 and a beta of 1.40. The business's 50-day moving average price is GBX 8.29 and its 200-day moving average price is GBX 7.44.

About Allergy Therapeutics

(Get Free Report)

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Allergy Therapeutics Right Now?

Before you consider Allergy Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Allergy Therapeutics wasn't on the list.

While Allergy Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report
Like this article? Share it with a colleague.